The CDC's Advisory Committee on Immunization Practices recommended the removal of the preservative thimerosal in seasonal influenza vaccines at their meeting.

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

In a new consensus statement, the European Society of Cardiology has declared vaccinations for common infections to be a ...

The US Advisory Committee on Immunization Practices voted in June to stop recommending certain kinds of flu vaccines, a ...

Thimerosal Triggers Toxic Debate While the new panel showed little conflict over the 2025-2026 seasonal flu vaccine recommendations, thimerosal fueled sharp reactions among members and outside ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

Influenza significantly impacted adults aged 50 to 64 years and younger adults with chronic conditions, but risk can be reduced with RIV.

Recommendations on the strain composition of influenza virus vaccines for the 2025-2026 US season have been issued by the Food and Drug Administration (FDA). The recommendations were made ...

The FDA made recommendations to vaccine manufacturers for the virus strains to be used in the next batch of flu vaccines, according to a March 13 news release from the agency. Respiratory illness ...

The U.S. FDA issues flu vaccine strain recommendations for 2025-2026 on its own without advisory input. Read more here.

The Food and Drug Administration has issued recommendations for the composition of influenza shots for the upcoming respiratory virus season, but without input from its independent vaccine advisers.